These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11396280)

  • 1. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
    Lipman J; Wallis SC; Rickard CM; Fraenkel D
    Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria.
    Roos JF; Lipman J; Kirkpatrick CMJ
    Intensive Care Med; 2007 May; 33(5):781-788. PubMed ID: 17342515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
    Van der Werf TS; Fijen JW; Van de Merbel NC; Spanjersberg R; Möller AV; Ligtenberg JJ; Tulleken JE; Zijlstra JG; Stegeman CA
    Intensive Care Med; 1999 Dec; 25(12):1427-31. PubMed ID: 10660852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
    Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
    J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime versus cefpirome: the importance of creatinine clearance.
    Lipman J; Wallis SC; Boots RJ
    Anesth Analg; 2003 Oct; 97(4):1149-1154. PubMed ID: 14500173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
    Jacolot A; Incagnoli P; Edouard AR; Tod M; Petitjean O; Samii K; Mimoz O
    Intensive Care Med; 1999 May; 25(5):486-91. PubMed ID: 10401943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.
    Masich AM; Kalaria SN; Gonzales JP; Heil EL; Tata AL; Claeys KC; Patel D; Gopalakrishnan M
    Pharmacotherapy; 2020 Mar; 40(3):211-220. PubMed ID: 31957057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.
    Joukhadar C; Klein N; Mayer BX; Kreischitz N; Delle-Karth G; Palkovits P; Heinz G; Müller M
    Crit Care Med; 2002 Jul; 30(7):1478-82. PubMed ID: 12130965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.
    Lipman J; Wallis SC; Rickard C
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2559-61. PubMed ID: 10508045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.
    Frazee E; Rule AD; Lieske JC; Kashani KB; Barreto JN; Virk A; Kuper PJ; Dierkhising RA; Leung N
    Am J Kidney Dis; 2017 May; 69(5):658-666. PubMed ID: 28131530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
    Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
    Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.
    Sauermann R; Delle-Karth G; Marsik C; Steiner I; Zeitlinger M; Mayer-Helm BX; Georgopoulos A; Müller M; Joukhadar C
    Antimicrob Agents Chemother; 2005 Feb; 49(2):650-5. PubMed ID: 15673747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.
    Hollenstein U; Brunner M; Mayer BX; Delacher S; Erovic B; Eichler HG; Müller M
    Clin Pharmacol Ther; 2000 Mar; 67(3):229-36. PubMed ID: 10741625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the pharmacokinetics of cefpirome sulphate in the elderly.
    Sugihara H; Narita N; Takatsu R; Horiuchi M; Yonenami K; Hotta M; Shibahara K; Kamo T; Negishi Y
    J Clin Pharm Ther; 1998 Oct; 23(5):375-9. PubMed ID: 9875686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics of cefpirome in patients with renal impairment.
    Lameire N; Malerczyk V; Drees B; Lehr K; Rosenkranz B
    Clin Pharmacol Ther; 1992 Jul; 52(1):24-30. PubMed ID: 1623690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.